Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 23.18 USD -0.94%
Market Cap: 163.4m USD
Have any thoughts about
Cidara Therapeutics Inc?
Write Note

Cidara Therapeutics Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cidara Therapeutics Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Cidara Therapeutics Inc
NASDAQ:CDTX
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Inventory
$4.5B
CAGR 3-Years
13%
CAGR 5-Years
18%
CAGR 10-Years
16%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$3.4B
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Inventory
$7.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.1B
CAGR 3-Years
48%
CAGR 5-Years
46%
CAGR 10-Years
51%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Inventory
$3B
CAGR 3-Years
14%
CAGR 5-Years
18%
CAGR 10-Years
38%
No Stocks Found

Cidara Therapeutics Inc
Glance View

Market Cap
163.3m USD
Industry
Biotechnology

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

CDTX Intrinsic Value
9.28 USD
Overvaluation 60%
Intrinsic Value
Price

See Also

Back to Top